AstraZeneca starts trial of Covid-19 antibody treatment

The London-listed firm, already among the leading players in the global race to develop a successful vaccine, said the study would evaluate if AZD7442, a combination of two monoclonal antibodies (mAbs), was safe and tolerable in up to 48 healthy participants between the ages of 18 and 55 years.

from Hindustan Times - world https://bit.ly/3jaAMMo
https://ift.tt/2zbki14